Navigation Links
Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $32.65 Million of Senior Convertible Notes
Date:12/4/2008

SEATTLE, Dec. 5 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI" or the "Company") (Nasdaq and MTA: CTIC) today announced that a single institutional investor shall purchase, for $32.65 million, newly issued 10% Convertible Senior Notes due 2011 (the "Notes"), with a conversion price of $0.137 per share.

The new Notes would have a $32.65 million initial principal balance and feature a make-whole provision entitling the holder, upon any conversion of the Notes, to receive the interest payable through scheduled maturity, less any interest paid before conversion.

The Company has also agreed to repurchase from the investor, for approximately $29 million, approximately $30 million aggregate principal amount of outstanding 15% Convertible Senior Notes, Series B 18.33% Convertible Senior Notes and 9.66% Convertible Senior Notes (collectively, the "Repurchased Notes") that were issued in June, August and October 2008, respectively. For such repurchase, the Company will use approximately $16.4 million of the proceeds from the offering of the new Notes, plus funds to be released to the Company from the escrow account that was established to pay the make-whole and interest payments on the Repurchased Notes. Warrants to purchase approximately 5.15 million shares of common stock which are held by the investor are also being surrendered to the Company and will be cancelled. The Company expects to receive net proceeds of approximately $16.3 million from the new Notes (before payment of fees and expenses), after the repurchase of the Repurchased Notes and prior to depositing approximately $9.8 million in escrow for the new Notes' make-whole provision. The new Notes will rank equal in right of payment with all existing and future unsecured senior indebtedness of the Company.

In addition, the Company obtained a conditional put option to require the investor to purchase up to $6 million of its Series C 10% Co
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
2. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
3. ARYx Therapeutics, Inc. Files Registration Statement for Initial Public Offering
4. Nile Therapeutics, Inc. Adds to Executive Management Team
5. Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
6. Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
7. Cell Therapeutics, Inc. (CTI) Announces 2007 Annual Shareholders Meeting Results
8. Northwest Biotherapeutics, Inc. Announces Appointment of Chief Financial Officer
9. Nile Therapeutics, Inc. to Present at Upcoming BIO Investor Forum
10. Hyperion Therapeutics, Inc. Announces Senior Management Team and $15M Financing Event
11. Cell Therapeutics, Inc. (CTI) BIO Presentation to Be Webcast

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)... , NEW YORK, Nov. 25 Reportl...ort is available in its catalogue: ,, Brazil B..., http://www.reportlinker.com/p0165503/Brazil-...tml ,, Brazil Bioethanol Market Analysis and F...provides detailed analysis and forecasts of the gl...
(Date:11/24/2009)... The New York investment bank KTA ...EU) has agreed an AU$6.7 mil convertible note priv...The private placement was arranged by KTA Capital ... , New York (PRWEB) Novem...t bank KTA Capital, LLC ("KTA Capital") ...
(Date:11/24/2009)... Health care employment grew by ...only one to show consistent growth during the U.S....ls remain in trouble, and health systems are comin...el, instead of just administrators. , ...are employment continued growing in October despit...
(Date:11/24/2009)...EATTLE,Nov.24/PRNewswire/--BlueMarbleEnergyCorp.an...pmentAuthority(OPDA)wererecentlyawarded$2millionby...ard(CERB)inaprivate/publicpartnershiptoconstructth...olnCounty,WA. ,, "Thisinvestmentwillsignificant...0greenjobstoLincolnCounty,"saidBlueMarbleEnergyCEO...
Breaking Biology Technology:Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 2Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 3Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 4Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 5Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 6Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 7Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 8Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 9Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 10KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 2The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 3The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 4Blue Marble Energy, OPDA Awarded $2M by WA's Community Economic Revitalization Board 2
...lcers each year in the US, PRINCETON, N.J., March...), provider of advanced wound care products,announ... the clinical usage,of its newly released MEDIHONE...mum Honey presented at the annual American Profess...ld the second week in March in Forth,Worth, Texas,...
...aunch..., WAYLAND, Mass., March 20 Tourtellotte ...linical trials software, announces the,launch of i...rm for phase,II-IV studies. Trident,s unique param...of legacy IVRS technologies and promises to delive...nd ease-of-use to the straining,global clinical IV...
...nc., a,pioneer in drug discovery from marine micro...begun in a Phase 1b study evaluating the vascular,...h standard chemotherapy,in patients with non-small...ositive outcomes in a Phase 1 single-agent clinica...armacodynamics (PK/PD) and efficacy of NPI-2358,in...
Other Biology Technology:Derma Sciences Announces Clinical Poster on Use of MEDIHONEY(TM) Wound & Burn Dressings Wins First Place Award at APWCA 2Derma Sciences Announces Clinical Poster on Use of MEDIHONEY(TM) Wound & Burn Dressings Wins First Place Award at APWCA 3Derma Sciences Announces Clinical Poster on Use of MEDIHONEY(TM) Wound & Burn Dressings Wins First Place Award at APWCA 4Tourtellotte's New Trident IWR(TM) Eliminates 12-Week Study Setup Lead Time for Clinical Trials 2Tourtellotte's New Trident IWR(TM) Eliminates 12-Week Study Setup Lead Time for Clinical Trials 3Nereus Pharmaceuticals Initiates Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer Following Encouraging Phase 1 Data 2Nereus Pharmaceuticals Initiates Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer Following Encouraging Phase 1 Data 3
(Date:11/24/2009)...t keep weakened and flabby arteries from collapsin..., those stents are no longer needed -- once the ar...Previously, doctors had no choice but to leave the... University,s Department of Biomedical Engineering... that carries drugs where they,re needed, then dis...
(Date:11/24/2009)...UGE Antarctica has long held secrets of the earth...ently, there has been very little information on t...s of ice for millions of years. Now, a team of res...ve been funded to the tune of $10 million dollars ... to the bottom of things literally. These scienti...
(Date:11/23/2009)...New research presents strong evidence that the "sy...utdoor traffic-related pollution and indoor endoto...or the other exposure alone. , Environmental h...UC) College of Medicine have shown that children e...icles and indoor endotoxin during early life are s...
Breaking Biology News(10 mins):A coating for life 2LSU gets to the bottom of things -- in Antarctica 2Exposure to both traffic, indoor pollutants puts some kids at higher risk for asthma later 2ICL Reports Continued Sequential Improvement for Third Quarter of 2009 62011 1ICL Reports Continued Sequential Improvement for Third Quarter of 2009 62011 2ICL Reports Continued Sequential Improvement for Third Quarter of 2009 62011 3ICL Reports Continued Sequential Improvement for Third Quarter of 2009 62011 4ICL Reports Continued Sequential Improvement for Third Quarter of 2009 62011 5ICL Reports Continued Sequential Improvement for Third Quarter of 2009 62011 6ICL Reports Continued Sequential Improvement for Third Quarter of 2009 62011 7Jackson 26amp 3B Coker Industry Report Addresses Health Care Reform 62010 1Jackson 26amp 3B Coker Industry Report Addresses Health Care Reform 62010 2Jackson 26amp 3B Coker Industry Report Addresses Health Care Reform 62010 3Slate Capital Group and New Markets Venture Partners Acquire eCoast Sales Solutions 62008 1Slate Capital Group and New Markets Venture Partners Acquire eCoast Sales Solutions 62008 2Slate Capital Group and New Markets Venture Partners Acquire eCoast Sales Solutions 62008 3
...AMBRIDGE, Mass. (April 2, 2009) Whitehead Institu...ifiable prion proteins in yeast and have further c...f both beneficial and detrimental traits. , "The ...al are they evolved to be prions, or are they alw...," says Randal Halfmann, a research assistant in W...
...New diseases directly affect human survival and fo...bs. Leaf-cutting ants, one of a few groups of soci...t material to fertilize their underground fungal g... Smithsonian show that both the ants and their fun...t inside leaves, thus ensuring the health of their...
...AMBRIDGE, Mass.--Each year, hundreds of thousands ...rmic needles that penetrate too far under their sk...lleagues aims to prevent this from happening by ke...urely mechanical, is based on concepts borrowed fr... needle containing a filament that acts as a guide...
Other Biology News:Redefining what it means to be a prion 2Redefining what it means to be a prion 3Food security for leaf-cutting ants: Workers and their fungus garden reject endophyte invaders 2MIT: Novel needle could cut medical complications 2
UltraClean GelSpin Kit from Mo Bio Laboratories, Inc.
Rabbit Complement Lyophilized Powder from Equitech-Bio
Rabbit Anti-Human Histone H3, phospho (Ser10 / Ser28) Polyclonal Antibody, Unconjugated from Lake Placid Biologicals
UltraClean GelSpin Kit from Mo Bio Laboratories, Inc.
Biology Products: